The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Dec. 3, 4:48 PM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #50. Salix Pharmaceuticals, Ltd. Santarus

Acquirer: Salix Pharmaceuticals, Ltd. (SLXP)
Acquiree: Santarus (SNTS)
Details: Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has completed its previously announced tender offer for all outstanding shares of common stock par value $0.0001 per share, including the associated rights to purchase shares of Series A Junior Participating Preferred Stock, par value $0.0001 per share, of Santarus, Inc., (NASDAQ:SNTS), at a purchase price of $32.00 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. Following the tender offer, Salix completed the acquisition of Santarus earlier today through a merger under Section 251(h) of the General Corporation Law of the State of Delaware.

Salix Pharmaceuticals is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. Co.'s products include among others, XIFAXAN550® (rifaximin) Tablets, indicated for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years and older; XIFAXAN (rifaximin) tablets, indicated for the treatment of patients 12 years of age and older with travelers' diarrhea; and APRISO® (mesalamine) extended-release capsules, indicated for the maintenance of remission of ulcerative colitis.

Open the SLXP Page at The Online Investor »

Salix Pharmaceuticals is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. Co.'s products include among others, XIFAXAN550® (rifaximin) Tablets, indicated for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years and older; XIFAXAN (rifaximin) tablets, indicated for the treatment of patients 12 years of age and older with travelers' diarrhea; and APRISO® (mesalamine) extended-release capsules, indicated for the maintenance of remission of ulcerative colitis.

Open the SNTS Page at The Online Investor »

Company Name: 
Salix Pharmaceuticals Ltd
Website: 
www.salix.com
Sector: 
Drugs & Pharmaceuticals
Company Name: 
Santarus Inc
Website: 
www.santarus.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 50 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.